Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2020-05-08
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EX19
|
| gptkbp:brand |
gptkb:Retevmo
|
| gptkbp:CASNumber |
2152628-33-4
|
| gptkbp:chemicalFormula |
C29H31N7O3
|
| gptkbp:developedBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:genericName |
gptkb:selpercatinib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Retevmo
|
| gptkbp:indication |
gptkb:non-small_cell_lung_cancer
gptkb:RET_fusion-positive_thyroid_cancer medullary thyroid cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
RET kinase inhibitor
|
| gptkbp:pregnancyCategory |
Not recommended
|
| gptkbp:prescriptionStatus |
Rx-only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
constipation fatigue hypertension QT prolongation hepatotoxicity dry mouth |
| gptkbp:target |
gptkb:RET_proto-oncogene
|
| gptkbp:bfsParent |
gptkb:selpercatinib
|
| gptkbp:bfsLayer |
6
|